Condition: Systemic Lupus Erythematosus · Lupus Nephritis · Sponsor: Cabaletta Bio
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
This description comes directly from the study's public registry record.
Cabaletta Bio · 267 759 3100 · clinicaltrials@cabalettabio.com
Always discuss trial participation with your own doctor first.
| University of California Irvine | Orange, California, United States | Recruiting |
| UC Davis Health | Sacramento, California, United States | Recruiting |
| Yale University | New Haven, Connecticut, United States | Recruiting |
| University of Florida Health | Gainesville, Florida, United States | Active Not Recruiting |
| Mayo Clinic | Jacksonville, Florida, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
| Northwestern Memorial Hospital | Chicago, Illinois, United States | Recruiting |
| The University of Chicago Medical Center | Chicago, Illinois, United States | Recruiting |
| University of Kansas Medical Center | Kansas City, Kansas, United States | Recruiting |
| Tufts Medical Center | Boston, Massachusetts, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Boston Children's Hospital | Boston, Massachusetts, United States | Recruiting |
+ 11 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06121297